ライフサイエンスコーパス: Echinacea

1 ntly thought to be nine species in the genus Echinacea.

2 Green tea (29.8% [25 of 84]), echinacea (13.1% [11 of 84]), and essiac (9.5% [8 of 84]

3 The Echinacea alkamides may be assembled from two distinct m

4 ccurred during 7.1% of the URIs treated with echinacea and 2.7% of those treated with placebo (P =.00

5 07 children, including 337 URIs treated with echinacea and 370 with placebo.

6 ficant differences were detected between the echinacea and placebo groups for any of the measured out

7 stically significant differences between the echinacea and placebo groups.

8 e effect of chemically defined extracts from Echinacea angustifolia roots on rhinovirus infection.

9 ticularly on 3 species of purple coneflower (ECHINACEA:) because of the widespread use of purple cone

10 SNPs for any two Echinacea chloroplast genomes ranged from 181 to 910, an

11 rity were not statistically significant with echinacea compared with placebo.

12 ic (Allium sativum), ginkgo (Ginkgo biloba), echinacea (Echinacea purpurea), ginseng (Panax ginseng),

13 Echinacea, ephedra, garlic, ginkgo, ginseng, kava, St Jo

14 BoNT/A zinc metalloprotease inhibitors, from Echinacea, exemplified by the natural product d-chicoric

15 atistically significant effects of the three echinacea extracts on rates of infection or severity of

16 not support the ability of this dose of the echinacea formulation to substantively change the course

17 The Echinacea genus is exemplary of over 30 plant families t

18 supplements (ginkgo biloba, St John's wort, echinacea, ginseng, garlic, saw palmetto, kava kava, and

19 s in the placebo group, and 6.27 days in the echinacea group (between-group difference, -0.52 day [95

20 number of days of peak symptoms (1.60 in the echinacea group and 1.64 in the placebo group; P =.97),

21 =.97), number of days of fever (0.81 in the echinacea group vs 0.64 in the placebo group; P =.09), o

22 and 70 ng/L and 1 cell/hpf in the open-label echinacea group).

23 roup, 58 ng/L and 2 cells/hpf in the blinded echinacea group, and 70 ng/L and 1 cell/hpf in the open-

24 Echinacea groups received the equivalent of 10.2 g of dr

25 llness duration in the blinded and unblinded echinacea groups was 6.34 and 6.76 days, respectively, c

26 as 236 and 258 for the blinded and unblinded echinacea groups, respectively; 264 for the blinded plac

27 Echinacea has been widely used as an herbal remedy for t

28 Other components found in Echinacea, I3 and I4, were also inhibitors of the protea

29 e are few data on the efficacy and safety of echinacea in treating URIs in children.

30 Echinacea is a common botanical used in dietary suppleme

31 Echinacea is a widely used herbal remedy for treatment o

32 Echinacea is widely used to treat the common cold.

33 Echinacea may be helpful in the treatment or prevention

34 erence in duration between URIs treated with echinacea or placebo (P =.89).

35 y patients were randomized to receive either echinacea or placebo for up to 3 URIs over a 4-month per

36 95% CI, -69 to 13 points) toward benefit for echinacea (P = 0.089).

37 l groups: no pills, placebo pills (blinded), echinacea pills (blinded), or echinacea pills (unblinded

38 lls (blinded), echinacea pills (blinded), or echinacea pills (unblinded, open-label).

39 Echinacea preparations are widely used to treat the comm

40 Are Echinacea products associated with a reduced incidence a

41 but exploratory meta-analysis suggests that Echinacea products may be associated with a small reduct

42 flicting results, and there are a variety of echinacea products on the market with different phytoche

43 reatment trials, there was no association of Echinacea products with a shorter duration of colds.

44 Compared with placebo, unrefined echinacea provided no detectable benefit or harm in thes

45 An encapsulated mixture of unrefined Echinacea purpurea herb (25%) and root (25%) and E. angu

46 sativum), ginkgo (Ginkgo biloba), echinacea (Echinacea purpurea), ginseng (Panax ginseng), St John' s

47 Echinacea purpurea, as dosed in this study, was not effe

48 s received the equivalent of 10.2 g of dried echinacea root during the first 24 hours and 5.1 g durin

49 Ethanol extracts from Echinacea roots had potent activity as novel agonists of

50 John's wort, ginseng, echinacea, saw palmetto, and kava.

51 s not been successful for differentiation of Echinacea species.

52 bioactive compounds and chemical profiles in Echinacea with the goal of improving its human health be

53 Three preparations of echinacea, with distinct phytochemical profiles, were pr